Biosig Technologies (NASDAQ:STEX) Chairman Acquires $152,880.00 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom purchased 147,000 shares of the stock in a transaction on Thursday, May 21st. The stock was acquired at an average cost of $1.04 per share, for a total transaction of $152,880.00. Following the acquisition, the chairman owned 269,500 shares in the company, valued at approximately $280,280. This represents a 120.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The shares were sold at an average price of $1.07, for a total value of $13,652.13.

Biosig Technologies Trading Up 13.3%

NASDAQ:STEX opened at $1.28 on Friday. The firm has a 50-day simple moving average of $1.17. Biosig Technologies, Inc. has a twelve month low of $0.70 and a twelve month high of $14.11. The stock has a market cap of $231.86 million, a PE ratio of -0.13 and a beta of 1.58.

Biosig Technologies (NASDAQ:STEX) last announced its quarterly earnings data on Thursday, May 14th. The company reported $999.00 earnings per share for the quarter.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Weiss Ratings raised Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Needham & Company LLC decreased their price objective on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Wall Street Zen cut Biosig Technologies from a “hold” rating to a “strong sell” rating in a report on Sunday, April 5th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Biosig Technologies presently has an average rating of “Hold” and an average target price of $8.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.